3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
130
Lymphoma, Large B-Cell, Diffuse
101
Lymphoma, Follicular
90
Leukemia, Lymphocytic, Chronic, B-Cell
82
Lymphoma
63
Lymphoma, B-Cell
43
Recurrence
31
Lymphoma, Mantle-Cell
30
Lymphoma, B-Cell, Marginal Zone
23
Neoplasms
22
Leukemia
10
Hematologic Diseases
10
Lymphatic Diseases
8
Multiple Myeloma
7
Immunoproliferative Disorders
6
Hematologic Neoplasms
6
Waldenstrom Macroglobulinemia
5
Lymphoproliferative Disorders
5
Leukemia, B-Cell
5
Arthritis, Rheumatoid
5
Hodgkin Disease
4
Lymphoma, T-Cell
3
Leukemia, Myeloid, Acute
3
Immune System Diseases
3
Dendritic Cell Sarcoma, Interdigitating
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Peripheral
2
Interventions
Fulvestrant
9
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
Cetuximab
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
binimetinib
2
Topotecan
2
NVP-BKM120
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tipifarnib
1
talazoparib
1
sotorasib
1
ruxolitinib
1
olaparib
1
obinutuzumab
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA